Efficacy of Qingpeng ointment (a Tibetan medicine) for acute gouty arthritis: a multi-center, randomized, double-blind, placebo-controlled trial
Ya-Xi Shang,Shu-Feng Wei,Ke-Peng Yang,Yuan Liu,Su Wei,Xia Dong,Xin-Chang Wang,Zhi-Min Xie,Ru-Lu Fang,Li-Na Liang,Xiu-Feng Li,Lei Xu,Mu-Zhi Chen,Kai-Xian Zhang,Ji-Yong Huang,Le Wang,You-Guo Yang,Hong-Li Liao,Gui-E Xing,Yu-Ping Zheng,Xiao-Fen Li,Jing-Lian Lin,Cheng-Qian Shi,Yong-Ping Zeng,Li-Dan Mo,Fan Sun,Xiao-Peng Li,Zhuo Zhang,Kai Chen,Zhao-Chun He,Jian-Ping Liu
DOI: https://doi.org/10.1186/s12906-023-04328-7
2024-01-04
Abstract:Background: This study aims to assess the efficacy and safety of Qingpeng ointment (QPO), a Tibetan medicine for alleviating symptoms in individuals with acute gouty arthritis (AGA). Methods: This study was a randomized, double-blind, placebo-controlled trial that involved individuals with AGA whose joint pain, as measured on a visual analog scale (VAS) from 0 to 10, was equal to or greater than 3. The participants were randomly assigned to either the QPO or the placebo group and received their respective treatments twice daily for seven consecutive days. In case of intolerable pain, the participants were allowed to use diclofenac sodium sustained-release tablets as a rescue medicine. The primary outcomes measured were joint pain and swelling, while the secondary outcomes included joint mobility, redness, serum uric acid levels, C-reactive protein levels, and the amount of remaining rescue medicine. Any adverse events that occurred during the trial were also recorded. Results: A total of 203 cases were divided into two groups, with balanced baselines: 102 in the QPO group and 101 in the placebo group. For joint pain, differences between the groups were notable in the VAS scores [1.75 (0, 3.00) versus 2.00 (1.00, 3.50); P = 0.038], changes in VAS [5.00 (3.00, 6.00) versus 4.00 (2.00, 6.00); P = 0.036], and disappearance rate [26.47% compared to 15.84%; P = 0.046] after treatment. Concerning joint swelling, significant between-group differences were observed in the VAS scores [1.00 (0, 2.30) versus 2.00 (0.70, 3.00); P = 0.032] and disappearance rate [33.33% compared to 21.78%; P = 0.046] at treatment completion. The QPO group exhibited a statistically significant mobility improvement compared to the placebo group (P = 0.004). No significant differences were found in other secondary outcomes. Five patients, four from the QPO group and one from the other, encountered mild adverse events, primarily skin irritation. All of these cases were resolved after dosage reduction or discontinuation of the medication. Conclusions: Compared to the placebo, QPO exhibits positive effects on AGA by alleviating pain, reducing swelling, and enhancing joint mobility, without causing significant adverse effects. Trial registration: ISRCTN34355813. Registered on 25/01/2021.